|[February 27, 2013]
Extraordinary General Meeting of Diamyd Medical AB Cancelled
STOCKHOLM --(Business Wire)--
The Extraordinary General Meeting of Diamyd Medical AB
(STO:DIAM-B) (Pink Sheets:DMYDY) summoned to for March 13, 2013 is
The group of shareholders who had previously requested an Extraordinary
General Meeting of Diamyd Medical AB has formally withdrawn their
request. The Extraordinary General Meeting summoned to for March 13,
2013 is therefore cancelled.
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in
Stockholm, Sweden. The Company's development project consists of the
protein GAD for the treatment and prevention of autoimmune diabetes. Two
Swedish researcher-initiated Phase II studies are ongoing. One study
evaluates whether GAD can prevent type 1 diabetes in children who are at
high risk of develoing the disease and one study evaluates whether GAD
in combination with relatively high doses of vitamin D and ibuprofen can
preserve the body's own ability to control the blood sugar level in
children and adolescents newly diagnosed with type 1 diabetes.
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation
(USA) and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by
the Pink OTC Markets and the Bank of New York Mellon (PAL). Further
information is available on the Company's website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ)
Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone (News - Alert): +46 8 661 00 26,
Fax: +46 8 661 63 68 E-mail: email@example.com.
Reg. no: 556530-1420
This information was brought to you by Cision http://news.cision.com
[ Back To Technology News's Homepage ]